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In the current issue of Oncotarget, a 10-year follow-
up study by Powe et al. reports that women receiving beta-
blocker  therapy  for  hypertension  showed  a  significant 
reduction in breast cancer metastasis, recurrence and 
mortality. These findings provide first clinical evidence 
in  support  of  earlier  in  vitro  findings  by  the  same 
research  group  reporting  significant  norepinephrine-
induced stimulation of cell migration that was inhibited 
by the beta-blocker propranolol or by the γ-aminobutyric 
acid (GABA)-mediated reduction in cAMP-dependent 
signaling in cancer of the colon, prostate and breast [1-
4]. Additional breast cancer-stimulating mechanisms that 
may have been inhibited by beta-blocker therapy include 
beta-adrenergic  receptor  (β-AR)-mediated  proliferation 
of cancer cells and the β-AR-mediated activation of the 
arachidonic acid (AA) cascade as well as β-AR-mediated 
modulation of G-protein inwardly rectifying K+-channels 
observed in vitro studies by another laboratory [5, 6]. 
Collectively, these findings identify signal transduction 
pathways  downstream  of  β-ARs  as  important  positive 
regulators of progression and metastasis in these cancers 
and represent a promising new target for the therapy and 
prevention of such malignancies. 
Beta-ARs  are  a  family  of  G-protein  coupled 
receptors that initiate multiple signaling cascades, 
including  the  adenylyl  cyclase/cAMP/PKA/CREB 
pathway which transactivates the epidermal growth 
factor receptor (EGFR) pathway, the Src/STAT pathway 
as well as the arachidonic acid (AA) cascade [7-11]. The 
catecholamine stress neurotransmitters noradrenaline and 
adrenaline (synonyms: norepinephrine and epinephrine) 
are  the  physiological  agonists  for  β-ARs  [12].  These 
neurotransmitters are not only released from the adrenal 
medulla as a response to psychological and physical 
stress but also regulate cell and organ responses to the 
sympathetic branch of the autonomic nervous system [13, 
14]. In turn, the synthesis and release of noradrenaline 
and adrenaline in the adrenal medulla and sympathetic 
nerves are regulated by nicotinic acetylcholine receptors 
(nAChRs)[10]. On the other hand, the neurotransmitter 
GABA  serves  as  the  physiological  inhibitor  of  β-AR 
signaling by blocking the activation of adenylyl cyclase 
via  the  inhibitory  G-protein  (Gαi)-coupled GABAB 
receptor [15]. 
First  evidence  for  a  regulatory  role  of  β-ARs  in 
cancer cells was provided in 1989 by an in vitro study 
that  showed  a  significant  increase  in  the  proliferation 
of human lung adenocarcinoma cells in response to the 
β-AR agonist isoproterenol with the general β-blocker 
propranolol inhibiting this response [16]. Later 
investigations revealed similar epinephrine-induced 
effects in these cells that were blocked by propranolol and 
were depended on β-AR mediated increase in intracellular 
cAMP [17]. Discoveries that the nicotine-derived and 
highly carcinogenic nitrosamine (4)-methylnitrosamino-
1-(3-pyridyl)-1-butanone (NNK) is a high affinity agonist 
for  β1-and  β2-ARs  [18]  as  well  as  for  nAChRs  [19] 
provided a first etiological link between the activation of 
nAChR-regulated β-AR signaling and the development 
of smoking-associated cancers. It has thus been shown 
that NNK stimulates the proliferation of human lung 
adenocarcinoma cells and their normal cells of origin, small 
airway epithelial cells, via a cAMP-dependent signaling 
cascade that includes activation of the transcription factor 
CREB as well as the PKA-dependent transactivation of 
the EGFR pathway and the β-AR-mediated release of AA 
[9, 18, 20]. This signaling cascade was not only stimulated 
by direct binding of NNK to β-ARs [18] but additionally 
by the α7nAChR-mediated production of noradrenaline 
and adrenaline in small airway epithelial cells and lung 
adenocarcinoma  cells  [21].  These  in  vitro  findings 
were further corroborated by reports that epinephrine 
promoted while propranolol inhibited the development 
of NNK-induced lung adenocarcinomas in hamsters 
[22]. In addition, chronic nicotine-induced progression of 
xenografts from a human lung adenocarcinoma cell line 
was associated with increased systemic levels of stress Oncotarget 2010; 1:  466 - 469 467 www.impactjournals.com/oncotarget
neurotransmitters  and  upregulation  of  nAChRs,  cAMP, 
p-CREB and p-ERK in the tumor cells while treatment of 
the mice with GABA inhibited all of these responses. In 
analogy to these findings, it was also shown that cell lines 
from pancreatic ductal adenocarcinomas were stimulated 
in their growth via NNK or isoproterenol-induced β-AR 
signaling [23] and that the beta-blocker propranol inhibited 
the development of NNK-induced pancreatic cancer in 
hamsters  [24]  while  inducing  apoptosis  in  pancreatic 
cancer  cells  in  vitro  [25].  Moreover,  nicotine  induced 
significant  progression  of  pancreatic  cancer  xenograft 
growth  that  was  associated  with  a  significant  systemic 
increase in stress neurotransmitters and upregulation of 
cAMP p-CREB and p-ERK in xenograft tissues. In turn, 
GABA blocked xenograft growth and the associated 
upregulation of cAMP-dependent signaling in response 
to nicotine [26]. Cell lines from human gastric and colon 
cancers also produced noradrenaline in response to nicotine 
treatment and the resulting increase in cell proliferation 
and angiogenesis was inhibited by propranolol [27-29]. 
It hence appears that the most common human cancers 
are not only stimulated by stress neurotransmitters in the 
systemic circulation but additionally produce their own 
noradrenaline and adrenaline.
Emerging  research  additionally  suggests  an 
important stimulating role of psychological stress in the 
progression, angiogenesis and metastasis of numerous 
cancers. It has thus been shown that social stress in mice 
increased the metastasis of breast cancer xenografts 
[30] and that stress induced by passive restraint as well 
as treatment with epinephrine had similar effects on 
ovarian cancer [31] while social isolation stress of mice 
significantly  increased  angiogenesis  and  metastasis  of 
colon cancer xenografts [32, 33] . Interestingly, treatment 
with  propranolol  significantly  reduced  these  effects. 
Moreover, recent studies with lung adenocarcinoma 
xenografts have shown a significant stimulation of tumor 
progression in mice exposed to social stress, an effect 
associated with upregulation of nAChR subunits alpha7 
and alpha4 and accompanied by systemic increase in stress 
neurotransmitters, reduction of GABA and activation of 
the cAMP/P-CREB/ERK pathway in tumor tissues [34]. 
Mechanisms such as this may contribute to the ethnic 
and racial differences in the smoking-related risk of lung 
cancer [35] while additionally providing a mechanistic 
explanation for reports that psychological stress is a 
significant  predictor  of  lung  cancer  mortality  [36]  and 
that lung cancer patients with a high rate of psychological 
distress at the time of diagnosis also have a history of 
pre-existing psychological stress [37]. In addition, the 
anxiety of patients diagnosed with cancer represents an 
additional form of stress that may counteract the efficacy 
of cancer therapy. It has thus been shown in mouse models 
of post-operative metastasis that propranolol and a COX-
2  inhibitor  given  before  and  after  surgical  removal  of 
primary melanoma cell or Lewis lung carcinoma cell 
foot pad implants had significantly fewer post-operative 
metastases than controls [38].
In summary, beta-blockers that have been safely used 
as cardio-vascular therapeutics for decades, and GABA 
that has been a safe nutritional supplement for many 
years, significantly reduce the proliferation, progression, 
angiogenesis and metastasis of the most common human 
malignancies, including adenocarcinoma of the breast, 
lung, pancreas, prostate, colon and stomach as well as 
ovarian cancer [39]. These agents should therefore be 
rapidly moved into clinical applications to increase the 
efficacy  of  currently  available  cancer  therapeutics  and 
cancer surgery. In addition, nutritional supplementation 
with GABA should be explored for the prevention of 
cancer in individuals at risk (e.g. current and former 
smokers). 
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